Understanding the Glutamic Acid Decarboxylase Antibodies (GAD 65) blood test

The Glutamic Acid Decarboxylase Antibodies (GAD 65) blood test measures antibodies directed against GAD 65, an enzyme involved in the production of gamma-aminobutyric acid (GABA), a key neurotransmitter in the brain and pancreas.

When the immune system mistakenly targets GAD 65, it can damage insulin-producing beta cells in the pancreas, leading to autoimmune diabetes. GAD 65 antibodies are most commonly associated with type 1 diabetes and latent autoimmune diabetes in adults (LADA), but may also be present in certain neurological autoimmune conditions.

This test is widely used to identify autoimmune causes of diabetes, differentiate diabetes subtypes, and support investigation of neurological symptoms with suspected autoimmune origin.

When a Glutamic Acid Decarboxylase Antibodies (GAD 65) test is recommended

This test is recommended when autoimmune involvement is suspected in glucose regulation or neurological function. Autoimmune diabetes can initially resemble type 2 diabetes, making antibody testing crucial for correct diagnosis and management.

Testing may be appropriate if you:

• Have newly diagnosed diabetes with atypical features
• Have diabetes diagnosed in adulthood but require insulin early
• Have poor response to oral diabetes medications
• Have a personal or family history of autoimmune disease
• Have unexplained neurological symptoms
• Are being assessed for latent autoimmune diabetes in adults (LADA)
• Have suspected autoimmune neurological conditions
• Require clarification of diabetes type

Benefits of the Glutamic Acid Decarboxylase Antibodies (GAD 65) test

• Identifies autoimmune diabetes
  Confirms immune-mediated beta cell damage.
• Differentiates diabetes subtypes
  Helps distinguish type 1, type 2, and LADA.
• Supports early and appropriate treatment
  Guides insulin and management decisions.
• Useful in adult-onset diabetes assessment
  Detects autoimmune diabetes presenting later in life.
• Aids investigation of neurological autoimmunity
  Relevant in selected neurological conditions.
• Improves diagnostic accuracy
  Reduces misclassification of diabetes.
• Simple blood test with no preparation required
  No fasting or lifestyle changes needed.
• Provides clear, clinically actionable results
  Supports personalised care planning.

How the test is carried out

We offer two convenient UK-wide testing options:

Clinic-based blood testing

• Choose your nearest UK clinic
• A healthcare professional collects a blood sample
• The sample is analysed in a certified laboratory
• Results are issued once testing is complete

Home or hotel blood collection (+£60)

• A qualified phlebotomist visits your home, workplace, or hotel
• Blood is collected at a time convenient for you
• No clinic visit required
• Available nationwide across the UK

Both options provide the same laboratory accuracy and clinical reliability.

Understanding your Glutamic Acid Decarboxylase Antibodies (GAD 65) results

Negative GAD 65 antibodies

No GAD 65 antibodies detected. This suggests no evidence of autoimmune activity related to GAD 65 at the time of testing.

Typical UK interpretation:

• Negative / Within reference range

Diabetes, if present, is more likely non-autoimmune.

Low to moderate positive GAD 65 antibodies

Detectable antibodies suggest autoimmune involvement, often seen in early or slowly progressive autoimmune diabetes.

Typical UK interpretation:

• Positive / Above reference range

Clinical correlation and follow-up testing may be advised.

High GAD 65 antibody levels

High antibody levels strongly suggest active autoimmune disease, commonly associated with type 1 diabetes or LADA.

Typical UK interpretation:

• Strongly positive

Endocrinology referral and management adjustment are often recommended.